NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$659.00
Cat.#: 11230 | ||||
Product Name: Human GPC3 Protein | ||||
Size : 10 µg, 50 µg and 100 µg | ||||
Synonyms: DGSX;GTR2-2;MXR7;OCI-5;SDYS;SGB;SGBS;SGBS1 | ||||
Target: GPC3 | ||||
UNIPROT ID: P51654 | ||||
Description: Recombinant Human GPC3 Protein with N-terminal Human Fc tag | ||||
Background: Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2009] References: Fu Ying,Urban Daniel J,Nani Roger R et al. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.[J] .Hepatology, 2019, 70: 563-576. Zhang Yi-Fan,Ho Mitchell,Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.[J] .Sci Rep, 2016, 6: 33878. | ||||
Species/Host: HEK293 | ||||
Molecular Weight: The protein has a predicted molecular mass of 43.3 kDa after removal of the signal peptide. | ||||
Molecular Characterization: hFc(Glu99-Ala330) GPC3(Asp511-Ser560) | ||||
Purity: The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining. | ||||
Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization. | ||||
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. | ||||
|